Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer.
The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Marinus R
MR
Heideman
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. University of Basel, Basel, Switzerland.
Anna
A
Frei
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. University of Basel, Basel, Switzerland. nancy.hynes@fmi.ch.
Nancy E
NE
Hynes
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D018931:Antineoplastic Agents, Hormonal; D047628:Estrogen Receptor alpha; D018398:Homeodomain Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases